Clinical Trial Update: Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of a hepatocyte growth factor (HGF) plasmid vector to improve perfusion in critical limb ischemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Artery Disease

Drugs mentioned

• HGF plasmid vector (hepatocyte growth factor plasmid)

Snippet

Sponsor: AnGes USA, Inc. | Conditions: Arterial Occlusive Disease, Peripheral Vascular Disease | Phase 2 | Status: COMPLETED